Physician profile
Matthew Eden
NPI 1609408343
$7,234.19
in general payments reported to CMS, 2019-2025
26 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $343 · 2023: $2,489 · 2024: $2,913 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,890.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,447.57 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $1,228.87 | 2022-2025 | Omnipod |
| Novo Nordisk INC | $894.59 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $731.58 | 2023-2025 | |
| Cequr Corporation | $450.63 | 2022-2025 | Cequr Simplicity |
| Radius Health, INC. | $404.78 | 2023-2024 | Tymlos |
| Amneal Pharmaceuticals LLC | $302.95 | 2022-2025 | Unithroid |
| Recordati_rare_diseases_inc. | $287.91 | 2023-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $221.55 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $197.04 | 2023-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.15 | 2023-2025 | Jardiance |
| Ibsa Pharma INC. | $136.95 | 2022-2024 | Tirosint, Licart, Tirosint |
| Mannkind Corporation | $113.78 | 2023-2025 | Afrezza |
| Corcept Therapeutics | $112.54 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $108.39 | 2024-2025 | Gvoke Hypopen, Recorlev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $54.27 | 2023 | Crysvita |
| Dexcom, INC. | $52.27 | 2024 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $52.06 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $49.90 | 2023-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $43.03 | 2024 | Resmetirom |
| Amphastar Pharmaceuticals, INC. | $35.37 | 2024-2025 | |
| Medtronic, INC. | $28.39 | 2024 | Minimed 780g |
| Ultragenyx Pharmaceutical INC. | $27.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.44 | 2023 | |
| Ascensia Diabetes Care US INC. | $19.52 | 2024 | |
| Acella Pharmaceuticals, LLC | $16.55 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Eden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.